TAXIS Pharmaceuticals has raised $6,500,000 in private funding since inception, including a $2,000,000 B1 round in June, 2015 to advance TXA709 through nGLP preclinical development. A $4,000,000 B2 financing, scheduled for January, 2016, will be utilized to secure TXA709 IND status in 2H, ’16 while enabling the expansion of the Company’s gram-negative drug discovery initiatives.